Celgene shares fall as 4th-qtr and full year results are revealed

28 January 2016

Shares in US biotech firm Celgene (Nasdaq: CELG) fell by more than 6% during mid-morning trading today, after the company’s fourth quarter 2015 results revealed earnings had fallen short of analysts’ estimates by just four cents.

The company’s earnings per share (EPS) increased 17% to $1.18 per share in the fourth quarter on net product sales of $2.539 billion. but Wall Street analysts had predicted the company would earn $1.22 per share. EPS increased by 27% to $4.71 in 2015 from $3.71 for the full year of 2014.

At 10.30am (ET) shares were trading at 96.12.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK